This smallcap pharma company has zoomed by over 8.5% today
5paisa Research Team
Last Updated: 10th December 2022 - 12:21 pm
The stock has created a fresh 52-week high!
Gufic Biosciences Ltd, engaged in the manufacturing of active pharmaceutical ingredients has been trending on Dalal Street as it has soared 8.55% on 12th April from its previous close of Rs 247.85. The share has been trading in the green territory today. The scrip opened at Rs 257.30 and made a day’s high of Rs 283.50, at which it has created a fresh 52-week high.
Such tremendous reaction has come on the back of the company receiving permission from the Central Licensing Approving Authority, Central Drug Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, to manufacture and sell Isavuconazonium Sulfate API and finished formulation Isavuconazole for Injection 200 mg/vial. It is used in the treatment of Invasive Aspergillosis and Invasive Mucormycosis
Talking about its recent quarterly results, in Q3FY22, revenue grew by 3.31% YoY to Rs 172.07 crore from Rs 166.56 crore in Q3FY21. On a sequential basis, the top-line was down by 11.37%. PBIDT (Ex OI) was reported at Rs 32.72 crore, up by 19.31% as compared to the year-ago period and the corresponding margin was reported at 19.02%, expanding by 256 basis points YoY. PAT was reported at Rs 21.03 crore, up by 36.01% from Rs 15.47 crore in the same quarter of the previous fiscal year. The PAT margin stood at 12.22% in Q3FY22 expanding from 9.29% in Q3FY21.
Gufic Biosciences is principally engaged in manufacturing and marketing active pharmaceutical ingredients, generic pharmaceuticals and related services. It is also one of the fastest-growing companies in top 100 pharma companies in India. The company has shifted its focus to international markets.
The stock has a 52-week high of Rs 283.50 and a 52-week low of Rs 107.60.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advance Charting
- Actionable Ideas
Trending on 5paisa
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.